AR127893A1 - CANCER THERAPY TARGETTING EGFR - Google Patents

CANCER THERAPY TARGETTING EGFR

Info

Publication number
AR127893A1
AR127893A1 ARP220103358A ARP220103358A AR127893A1 AR 127893 A1 AR127893 A1 AR 127893A1 AR P220103358 A ARP220103358 A AR P220103358A AR P220103358 A ARP220103358 A AR P220103358A AR 127893 A1 AR127893 A1 AR 127893A1
Authority
AR
Argentina
Prior art keywords
egfr
targetting
cancer therapy
component
tipiracil
Prior art date
Application number
ARP220103358A
Other languages
Spanish (es)
Inventor
Athanasios Pallis
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of AR127893A1 publication Critical patent/AR127893A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

Una combinación que comprende (a) un componente de anticuerpos anti-EGFR que comprende uno o dos anticuerpos anti-EGFR o porciones de unión a antígeno de los mismos y (b) un componente de trifluridina / tipiracilo.A combination comprising (a) an anti-EGFR antibody component comprising one or two anti-EGFR antibodies or antigen-binding portions thereof and (b) a trifluridine/tipiracil component.

ARP220103358A 2021-12-10 2022-12-07 CANCER THERAPY TARGETTING EGFR AR127893A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21306751 2021-12-10

Publications (1)

Publication Number Publication Date
AR127893A1 true AR127893A1 (en) 2024-03-06

Family

ID=80035092

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103358A AR127893A1 (en) 2021-12-10 2022-12-07 CANCER THERAPY TARGETTING EGFR

Country Status (3)

Country Link
AR (1) AR127893A1 (en)
TW (1) TW202339796A (en)
WO (1) WO2023105051A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227726B1 (en) 1995-03-29 2012-01-30 Taiho Pharmaceutical Co Ltd Uracyl-derivatives and antitumor effect potentiator and antitumor agent containing the same
AU770555B2 (en) 1998-08-17 2004-02-26 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
PL2132229T3 (en) 2007-03-01 2016-12-30 Recombinant anti-epidermal growth factor receptor antibody compositions
US20150231238A1 (en) * 2011-03-15 2015-08-20 Merrimack Pharmaceuticals, Inc. Overcoming resistance to erbb pathway inhibitors
PT3042669T (en) * 2013-09-06 2023-06-15 Taiho Pharmaceutical Co Ltd Antitumor agent and antitumor effect enhancer
US20200347140A1 (en) * 2017-08-30 2020-11-05 Symphogen A/S Compositions and methods for treating cancer with anti-egfr antibodies

Also Published As

Publication number Publication date
WO2023105051A1 (en) 2023-06-15
TW202339796A (en) 2023-10-16

Similar Documents

Publication Publication Date Title
CL2020003223A1 (en) Il-11 antibodies
EP3746119A4 (en) Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody
CL2023002105A1 (en) Antibody variable domains targeting cd33 and their uses
ECSP17005649A (en) HUMANIZED ANTI-TAU ANTIBODIES
PE20210167A1 (en) MULTI-SPECIFIC BINDING PROTEINS AND IMPROVEMENTS THROUGH THESE
EA202092000A1 (en) EGFR DIMERIZATION INHIBITORS AND THEIR USE
AR113224A1 (en) ANTIBODY CONJUGATES INCLUDING A STING AGONIST
BR112018013995A2 (en) oncolytic virus combination therapy and checkpoint inhibitor
ECSP20082648A (en) ANTI-SIRPA ANTIBODIES AND METHODS OF USING THEM
EA202091964A1 (en) COMBINED PRODUCT BASED ON Bcl-2 INHIBITOR AND MDM2 INHIBITOR AND ITS APPLICATION IN THE PREVENTION AND / OR TREATMENT OF DISEASES
EA202091810A1 (en) ANTIBODIES TO B7-H4 AND METHODS OF THEIR APPLICATION
CL2023000741A1 (en) Anti-nectin-4 antibody, conjugate that includes it and application thereof.
CO2022004743A2 (en) Antibodies directed to flt3 and use thereof
CO2021008665A2 (en) Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies
BR112022026236A2 (en) COMBINATION THERAPY OF IMMUNO-ONCOLOGY WITH IL-2 CONJUGATES AND ANTI-EGFR ANTIBODIES
BR112022017508A2 (en) EGFR, KRAS, BRAF AND OTHER TARGET INHIBITORS AND THEIR USE
CL2020003391A1 (en) Anti-steap1 antigen binding protein
AR127893A1 (en) CANCER THERAPY TARGETTING EGFR
CY1124183T1 (en) ANTI-SEZ6 DRUG CONJUGATES AND METHODS OF USE
CL2020002308A1 (en) Systems, apparatus, devices and methods for initiating or detonating tertiary explosive media by photon energy
AU2019379261A8 (en) Pharmaceutical combination of anti-CEACAM6 and either anti-PD-1 or anti-PD-l1 antibodies for the treatment of cancer
CO2023002034A2 (en) Multi-specific antigen-binding molecules against hiv and methods of use
CO2022009246A2 (en) Anti-c5 antibody for the treatment of neuromyelitis optica spectrum disorder
MX2020004074A (en) Combination product for the treatment of cancer.
MX2021012130A (en) Combinations of transcription inhibitors and immune checkpoint inhibitors for treatment of disease.